Yidu Tech's Subsidiary Yidu Cloud Participates in Successfully Approved National Key R&D Program under China's 14th Five-Year Plan

VCBeat learned today from Yidu Tech (stock code: 2158.HK), a company listed on the Hong Kong Stock Exchange, that its subsidiary Yidu Cloud has successfully secured approval for its participation in the application for the “Research on Prevention and Control of Common and Frequently Occurring Diseases” key special project under the National Key R&D Program during the 14th Five-Year Plan period—specifically, the project titled “Research on Predictive Warning and New Comprehensive Prevention and Treatment Strategies for Refractory and Relapsed Acute Myeloid Leukemia.”

Public information indicates that the project is led by the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences (Institute of Hematology, Chinese Academy of Medical Sciences), with the joint participation of five other entities: Peking University People’s Hospital, Beijing Institute of Genomics, Chinese Academy of Sciences (National Center for Bioinformation), Nanfang Hospital of Southern Medical University, Yidu Cloud, and Ascentage Pharma. As one of the participating units, Yidu Cloud is responsible for developing an early warning model for refractory and relapsed acute myeloid leukemia (AML) by integrating artificial intelligence with multidimensional data, building upon the medical data intelligence platform previously co-developed with hospitals. Furthermore, an AI-assisted diagnosis and treatment system will be constructed based on the novel AML diagnostic and therapeutic strategies generated by the project, thereby facilitating the promotion of both the prediction model for refractory and relapsed AML and the new diagnostic and therapeutic strategies.

Refractory relapse remains a major challenge in the treatment of acute myeloid leukemia (AML). Among patients with newly diagnosed AML, 20%–30% of younger adults and more than half of elderly patients fail to achieve complete remission due to drug resistance or treatment-related mortality. Furthermore, approximately 50% of patients who initially attain complete remission eventually experience relapse, ultimately progressing to refractory disease.

It is reported that since receiving official approval in 2019 to establish the National Clinical Research Center for Hematologic Diseases, the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences (also known as the Institute of Hematology, Chinese Academy of Medical Sciences) has been committed to deepening basic and clinical research on hematologic diseases, enhancing clinical research capabilities, and promoting the clinical application, translation, and dissemination of research findings.

“Research on New Strategies for Predictive Warning and Comprehensive Prevention and Treatment of Refractory and Relapsed Acute Myeloid Leukemia,” led by the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences (Institute of Hematology, Chinese Academy of Medical Sciences), focuses on the challenges in treating acute myeloid leukemia. Centering on novel diagnostic and therapeutic targets, the study leverages artificial intelligence technology to establish new diagnostic and treatment approaches through multi-center, prospective clinical cohorts. It aims to develop innovative therapeutic strategies targeting these new markers to promote hematopoietic recovery and improve treatment efficacy, while simultaneously validating the effectiveness of target-based diagnostic and therapeutic regimens through high-quality clinical research.

In the project, Yidu Cloud undertook the development of a predictive model for refractory/relapsed acute myeloid leukemia (AML) and a clinical diagnosis and treatment decision support system. By integrating artificial intelligence predictive models with novel diagnostic and therapeutic strategies identified in other research initiatives, the project established a data- and knowledge-driven decision support engine to facilitate personalized and precise AML treatment, thereby improving outcomes for patients with refractory/relapsed acute myeloid leukemia.

Industry experts attribute Yidu Cloud’s participation in the National Key R&D Program and its successful project initiation in collaboration with the lead institution to the company’s long-term dedication to medical data governance and comprehension. Yidu Cloud’s self-developed data platform performs in-depth governance on authorized, large-scale, multi-source heterogeneous medical data, transforming it into computable, full-lifecycle patient medical data. This enables deep insights to support data-driven clinical research and healthcare decision-making. The Yidu Cloud Data Science team has long collaborated with clinical experts to establish knowledge- and data-driven diagnosis and treatment models using scientific and innovative artificial intelligence algorithms, while its professional engineering system R&D team ensures the feasibility of clinical applications.

A representative from Yidu Tech stated that, going forward, Yidu Cloud will continue to deepen its expertise in medical data governance and comprehension, algorithmic modeling, and clinical decision support. By leveraging data science methodologies, the company aims to facilitate the smooth implementation of projects and accelerate the translation of technological innovations into practical outcomes.